Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $4.80 Analyst target: $52.38 Upside: 991.25%
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing novel therapies to address unmet medical needs in viral and liver diseases. The company is headquartered in South San Francisco, California.
See the full interactive analysis & chart →Informational only — not investment advice.